Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

NEXT STORY
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®
PREV STORY
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis

SAN DIEGO, March 30, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL), a biotechnology company ...

author_avatar
NASDAQ Market News

Growing Cases of Infectious and Chronic Diseases Expected to Fast-track the Growth of the Global Antibiotics Market by the end of 2027 – Exclusive Report [234 Pages] by Research Dive

author_avatar
NASDAQ Market News

CytomX Announces Data to be Presented at the American Association for Cancer Research Annual Meeting 2016

SOUTH SAN FRANCISCO, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics (Nasdaq:CTMX), a ...

author_avatar
NASDAQ Market News